- Immutep Limited (NASDAQ:IMMP) announced new interim data from 2nd line non-small cell lung cancer (NSCLC) patients (Part B) in the Phase 2 TACTI-002 trial.
- Part B evaluates Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in 36 patients.
- Median overall survival (OS) was 9.7 months for those who received chemo-free therapy of efti in combination with pembrolizumab, comparable with the current standard of care chemotherapy options in this 2nd line setting.
- Favorable sustained survival with 36.5% of patients alive at 18 months.
- Disease Control Rate (DCR) was 36.1%, and disease control (progression-free) in 25% of patients at six months.
- Durable responses of 10+ months in 5.6% (2/36) of patients, with both patients continuing in the trial for over 11 months and 24+ months.
- Efti, combined with pembrolizumab, continues to be safe and well-tolerated, with no new safety signals.
- Efti’s good safety profile to date compares favorably to the standard of care chemotherapy options.
- Price Action: IMMP shares are down 1.77% at $2.22 during the market session on the last check Monday.
Carolina Panthers Owner David Tepper Shakes Up Portfolio: Sells 8 Stocks, Ups Google Stake
Carolina Panthers owner David Tepper, who also manages the hedge fund Appaloosa Management, decreased the number of stocks in his portfolio from 30 to 22 throughout the third quarter.
